Martin G. Pomper
Johns Hopkins University School of Medicine
682 Papers
3.1K Citations
Martin G. Pomper is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 80, co-authored 601 publications. Previous affiliations of Martin G. Pomper include University of Illinois at Chicago & Johns Hopkins University.
Chat about Author
Papers
Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow
Jeffrey P. Leal,Steven P. Rowe,Vered Stearns,Roisin M. Connolly,Christos Vaklavas,Minetta C. Liu,Anna Maria Storniolo,Richard L. Wahl,Martin G. Pomper,Lilja B. Solnes +9 more
TL;DR: In this article , an image-processing workflow that incorporates both traditional image processing with AI technology and utilizes a standards-based approach for disease identification and quantitation to segment and classify tissue within a whole-body [18F]FDG PET/CT study was developed and examined.
Recent updates and developments in PET imaging of prostate cancer
TL;DR: A number of positron emission tomography radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer, including the bone-seeking agent Na 18 F and more tumor-specific compounds such as 11 C-choline and 18 F-fluciclovine.
Emission Tomography Correlates with Bactericidal Activity of Tuberculosis Drug Treatment
Stephanie L. Davis,Eric L. Nuermberger,Peter K. Um,Camille Vidal,Bruno Jedynak,Martin G. Pomper,William R. Bishai,Sanjay K. Jain +7 more
- 01 Jan 2009
TL;DR: By reducing animal numbers, these biomarkers will allow cost-effective studies of more expensive animal models of TB, and may also be useful as “point-of-care” methods to monitor TB treatment in humans.
18F-Labeled Radiotracers for Prostate-specific Membrane Antigen: Historical Perspective and Future Directions.
Steven P. Rowe,Ali Salavati,Rudolf A. Werner,Kenneth J. Pienta,Michael A. Gorin,Martin G. Pomper,Lilja B. Solnes +6 more
TL;DR: A review of radiofluorinated prostate-specific membrane antigen (PSMA) PET agents can be found in this article , including early clinical trials, key multicenter registration trials, emerging clinical agents, new compounds that are entering human use, and future directions for the field.
Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Michal Wegrzynowicz,Terry Jo Bichell,Barbara D. Soares,Meredith K. Loth,Jennifer L. McGlothan,Fatima S. Alikhan,Kegang Hua,Jennifer M. Coughlin,Hunter K. Holt,Christopher S. Jetter,Susumu Mori,Martin G. Pomper,Alexander P. Osmand,Tomás R. Guilarte,Tomás R. Guilarte,Aaron B. Bowman +15 more
TL;DR: The HD phenotypes present in animals 3 to 12 months of age make the BAC-225Q mice a unique and stable model of full-length mutant Htt associated phenotypes, including body weight loss, behavioral impairment and HD-like neurodegenerative phenotypes characteristic of juvenile-onset HD and/or late-stage adult-onsets HD.